3:25
MUK Nine b: OPTIMUM, paving the way to effectively treat newly diagnosed high-risk MM
Martin Kaiser
1:54
CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Katja Weisel
3:17
Results of the GMMG PERSPECTIVE trial: triple regimen for R/R multiple myeloma
Katja Weisel
2:56
Molecular subtypes of ALL: coming to a consensus
Bijal Shah
2:28
What can be learnt about using interferon in patients with myelofibrosis?
Jean-Jacques Kiladjian
0:56
Why one size should not fit all for multiple myeloma
Gareth Morgan
3:45
Reducing the risk of secondary malignancies in lymphoma
David Hodgson
1:13
Have novel drugs made stem cell transplantation obsolete?
David Maloney
1:31
Can ibrutinib be used as a first-line treatment in CLL?
Stephan Stilgenbauer
3:41
Long-term follow-up: AML17 trial of ATO and ATRA vs the standard of care in APL
Alan K. Burnett
2:19
Comparison of native vs pegylated asparaginase for HR Ph chromosome-negative ALL
Josep-Maria Ribera
1:46
Highlights from ASH 2016: whole-genome sequencing to identify genomic lesions in ALL
Anthony Moorman
1:25
Marginalized and high-risk multiple myeloma patients: how to address this issue
Joseph Mikhael
1:40
Benefits of early therapeutic intervention for high-risk smouldering multiple myeloma patients
Irene Ghobrial
2:10
Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy
Petra Langerbeins
8:29
Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Heinz Ludwig et al.
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals